Tempest Therapeutics, Inc.
TPST
$1.92
-$0.02-1.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.54M | 3.03M | 4.10M | 3.31M | 3.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.08M | 3.60M | 7.97M | 10.94M | 13.92M |
| Operating Income | -4.08M | -3.60M | -7.97M | -10.94M | -13.92M |
| Income Before Tax | -4.02M | -3.51M | -7.87M | -10.86M | -13.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.02M | -3.51M | -7.87M | -10.86M | -13.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.02M | -3.51M | -7.87M | -10.86M | -13.81M |
| EBIT | -4.08M | -3.60M | -7.97M | -10.94M | -13.92M |
| EBITDA | -4.01M | -3.53M | -7.90M | -10.87M | -13.87M |
| EPS Basic | -0.82 | -0.79 | -2.07 | -3.16 | -4.38 |
| Normalized Basic EPS | -0.51 | -0.49 | -1.29 | -1.97 | -2.74 |
| EPS Diluted | -0.82 | -0.79 | -2.07 | -3.16 | -4.38 |
| Normalized Diluted EPS | -0.51 | -0.49 | -1.29 | -1.97 | -2.74 |
| Average Basic Shares Outstanding | 4.91M | 4.44M | 3.80M | 3.44M | 3.15M |
| Average Diluted Shares Outstanding | 4.91M | 4.44M | 3.80M | 3.44M | 3.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |